Barry Cohen

Barry Cohen

Barry Cohen has nearly 30 years in communications and marketing, the majority in senior positions at three large international health care companies – Abbott Laboratories, Warner-Lambert (now part of Pfizer) and Bayer, Inc.

At Abbott, Cohen was a member of the company’s investor relations team, responsible for preparing all financial analyst presentations. He also oversaw the company’s award-winning annual and quarterly reports and was responsible for both the company’s investor seminar and annual shareholders’ meeting.

After relocating to Arizona, Cohen served as editor of M.D. News, a magazine for Phoenix-area physicians. Later he was a reporter for a weekly newspaper in a north Phoenix, where he specialized in business articles and profiles of local publicly traded companies.

To further his knowledge and understanding of financial markets, Cohen earned a series 7 broker’s license and was employed at Charles Schwab as a registered representative.  He returned to the communications field with CPRi Communications, where he wrote numerous case studies and bylined articles for the company’s clients in the health care information technology industry. Later, he worked for a Scottsdale, Ariz.-based investment bank preparing profiles of companies being offered for sale.

Recent Articles

Johnson & Johnson a Safe Play for Income

JNJ's financials are solid, and the company is making strides toward getting 11 new drugs approved by the end of 2015.

In Event of Bird Flu Pandemic, Vaccine Producers Likeliest to Prosper

A mutant strain of H5N1 could be spreading in Asia, meaning vaccine heavyweights might be going back to the drawing board.

Vertex Scores Big With Hepatitis Drug

The company's new hepatitis C medication, Incivek, is outselling Merck's drug by 4-to-1. What's more, it's close to adding another drug to its arsenal.

Insider Bets Big That Seattle Genetics Cancer Drug Can Buck Dendreon Effect

Similar drugs in Adcetris' high price range also faring well, which is cause for optimism, but SGEN's lack of other drugs near the end of the pipeline should make investors wary.

Share Prices of Bristol-Myers, Pfizer Could Jump on Positive Blood-Thinner Study Data

Rush to replace warfarin is a big opportunity for the drug industry, and this pair of pharmaceuticals could use the help.